论文部分内容阅读
目的:探究依达拉奉联合重组组织型纤溶酶原激活剂(rt-PA)对脑梗死(CI)患者的疗效影响。方法:选取于2013年5月~2015年10月期间我院收治的CI患者88例,随机分为对照组和观察组各44例,对照组给予依达拉奉治疗,观察组在对照组的基础上予以rt-PA溶栓治疗,观察两组治疗后的美国国立卫生院神经功能缺损评分(NIHSS)、疗效及血清肿瘤坏死因子-α(TNF-α)和白介素-6(IL-6)、白介素-12(IL-12)水平的变化。结果:两组治疗后NIHSS评分均较治疗前显著下降,且观察组较对照组下降更加显著,差异有统计学意义(P<0.05);观察组总有效率为77.27%,明显高于对照组的50.00%,差异有统计学意义(P<0.05),且两组患者在治疗过程中均未出现严重的不良反应。两组治疗后血清炎性因子水平均显著降低,差异具有统计学意义(P<0.05),且观察组改善程度均明显优于对照组,差异具有统计学意义(P<0.05)。结论:依达拉奉联合rt-PA能显著减轻CI患者的炎症反应,改善神经功能缺损程度,值得临床推广。
Objective: To investigate the therapeutic effect of edaravone combined with recombinant tissue plasminogen activator (rt-PA) on patients with cerebral infarction (CI). Methods: A total of 88 CI patients admitted to our hospital from May 2013 to October 2015 were randomly divided into control group (44 cases) and observation group (44 cases). The control group was treated with edaravone and the control group Based on the rt-PA thrombolytic therapy, the treatment of the National Institutes of Health neurological deficit score (NIHSS), efficacy and serum tumor necrosis factor-α (TNF-α) and interleukin -6 (IL-6) , Interleukin-12 (IL-12) levels. Results: The NIHSS scores of both groups were significantly lower than those before treatment, and the observation group was more significant than the control group (P <0.05). The total effective rate of the observation group was 77.27%, which was significantly higher than that of the control group 50.00%, the difference was statistically significant (P <0.05), and the two groups of patients in the course of treatment did not appear serious adverse reactions. Serum levels of inflammatory cytokines in both groups were significantly decreased after treatment, the difference was statistically significant (P <0.05), and the improvement in the observation group were significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion: Edaravone combined with rt-PA can significantly reduce the inflammatory response in patients with CI and improve the degree of neurological deficit, it is worth clinical promotion.